Frost N, Kollmeier J, Misch D, Vollbrecht C, et al. Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (>/= 50%) NSCLC: Real-world Results with Special Focus on PS >/= 2, Brain Metastases, and Steroids. Clin Lung Cancer 2021;22:411-422.
PMID: 33648877